Clinical Trial: A clinical study on the maintenance treatment of platinum-sensitive recurrent ovarian cancer patients who have previously received PARPi, combined with epalrestat and torvelinabucelumab rechallenge (China)

China, Aug. 18 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'A clinical study on the maintenance treatment of platinum-sensitive recurrent ovarian cancer patients who have previously received PARPi, combined with epalrestat and torvelinabucelumab rechallenge'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600130178

Registration Time: 2026/08/17

Type: Interventional study

Primary Sponsor: hunan cancer hospital

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=329106

Published by HT Digital Content Services with permission from Health Daily Digest....